Insights into healthcare and societal costs of subcutaneous injection and intravenous infusion of trastuzumab for HER2 positive breast cancer and rituximab for non-Hodgkin’s lymphoma in The Netherlands
The aim of this study was to investigate healthcare and societal costs associated with SC injections and IV infusions of two oncology drugs (i.e. trastuzumab and rituximab) in The Netherlands. The study results were presented in a poster presentation at ISPOR Barcelona 2018. Please find the publication of study results here.